Inaccurate labeling in CBD products

by Duncan Fisher

September 13, 2022 - 2 min read

A study published in ‘Science of the Total Environment’ (Gardener, et al., 851(1), 10 December 2022, 158110) has shown that the contents of nearly 60% of CBD products in America do not match their package labeling. Worryingly, some products surveyed also showed the presence of unlabeled contaminants, some of them potentially harmful. 

Only 42% of the samples contained the CBD percentage stated, and 58% were mislabeled outright. Nearly half contained less than 90% of what was claimed, and 18% contained over twice as much. Traces were found in edible products, furthermore, of lead, mercury, arsenic, cadmium, and phthalates. 

The Louisiana Department of Public Health has since produced an emergency rule governing the labeling, testing, and registration requirements for consumable hemp products.Limits are imposed for solvents, pesticides, microbials, and heavy metals, and for THC content. New labeling language is mandated as well, and packaging must state the size and number of servings within the package and provide a measuring device for determining serving size.  

On Wednesday, the Virginia Board of Agriculture and Consumer Services as well issued a finalized set of regulations for testing and labeling requirements for industrial hemp extracts intended for human consumption and foods. Topical products remain outside the scope of this regulation. Contaminant limits for microbiological, mycotoxins, and heavy metals and pesticide chemical residue tolerances must be the same as those allowed for cannabis products produced by pharmaceutical processors under existing legislation.

PureForm CBD, the active ingredient in DiolPure products, is not derived from hemp, and contains no THC or any of the solvents, pesticides, or soil metals associated with agricultural cannabis production. 



DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

 


 

 




Cannabigerol (CBG): Another promising cannabinoid?

Cannabigerol (CBG): Another promising cannabinoid?

For some good reasons, research and commercial attention is beginning to turn to cannabigerol, or 'CBG'. 
Read More

October 04, 2022 2 min read

Up close: Cannabinoids in Huntington's chorea

Up close: Cannabinoids in Huntington's chorea

In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time, show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream. 
Read More

October 03, 2022 3 min read

Up close: Cannabinoids in neurodegenerative diseases

Up close: Cannabinoids in neurodegenerative diseases

Modulation of cannabinoid receptor signaling should represent a viable therapeutic target in neurodegenerative diseases. 
Read More

September 30, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00
Shipping
Total

Shipping Address

Shipping Methods